Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.50 |
| ▸ | TNF | P01375 | 1/20 | 0.45 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.45 |
| ▸ | AHR | P35869 | 7/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | IKBKB | O14920 | 1/20 | 0.32 |
| ▸ | CHUK | O15111 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.31 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | TAF1 | P21675 | 1/20 | 0.31 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.31 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20354848 | 0.81 | TNF (0.55) | GPR84TNFRIPK1AHRIKBKB | |
| SCHEMBL30950714 | 0.81 | GPR84 (0.45) | GPR84TNFRIPK1AHRNR4A2 | |
| SCHEMBL18876104 | 0.81 | TNF (0.46) | GPR84TNFRIPK1AHRAR | |
| SCHEMBL1741436 | 0.78 | TNF (0.38) | GPR84TNFRIPK1AHRIKBKB | |
| SCHEMBL18876057 | 0.78 | TNF (0.38) | GPR84TNFRIPK1AHRIKBKB | |
| SCHEMBL10179175 | 0.78 | CSNK2A1 (0.41) | GPR84TNFRIPK1AHRIKBKB | |
| SCHEMBL29991075 | 0.78 | TNF (0.47) | GPR84TNFRIPK1AHRIKBKB | |
| SCHEMBL17392810 | 0.77 | GPR84 (0.41) | GPR84TNFRIPK1AHRIKBKB | |
| SCHEMBL5186145 | 0.75 | PTPRC (0.45) | GPR84TNFRIPK1IKBKBCHUK | |
| SCHEMBL2537028 | 0.74 | TNF (0.63) | GPR84TNFRIPK1AHRAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018033-B2 | Inhibitors of protein arginine deiminases | FORWARD THERAPEUTICS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240150313-A1 | TRI-SUBSTITUTED INDOLE BINDING FUNCTION 3 (BF3) COMPOUNDS AND METHODS FOR THEIR USE | UNIV BRITISH COLUMBIA (CA) | 2024-05-09 | — | — | US | disclosed |
| EP-4323372-A1 | TRI-SUBSTITUTED INDOLE BINDING FUNCTION 3 (BF3) COMPOUNDS AND METHODS FOR THEIR USE | The University Of British Columbia (CA) | 2024-02-21 | — | — | EP | disclosed |
| CN-116462814-A | Indolocarbazole covalent organic framework material and preparation method and application thereof | 江南大学 | 2023-07-21 | — | — | CN | disclosed |
| EP-4182320-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | Nido Biosciences, Inc. (US) | 2023-05-24 | — | — | EP | disclosed |
| WO-2022219541-A1 | TRI-SUBSTITUTED INDOLE BINDING FUNCTION 3 (BF3) COMPOUNDS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2022-10-20 | — | — | WO | disclosed |
| US-11453676-B2 | Inhibitors of protein arginine deiminases | FORWARD THERAPEUTICS, INC. (US) | 2022-09-27 | — | — | US | disclosed |
| WO-2022020342-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES, INC. (US) | 2022-01-27 | — | — | WO | disclosed |
| EP-1859798-B1 | N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | LILLY CO ELI (US) | 2015-12-30 | — | — | EP | disclosed |
| US-8044090-B2 | N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor | ELI LILLY (US) | 2011-10-25 | — | — | US | disclosed |
| WO-2006039717-A2 | METHODS OF DETERMINING PRECISE HERG INTERACTIONS AND ALTERING COMPOUNDS BASED ON SAID INTERACTIONS | NEURION PHARMACEUTICALS, INC. (US) | 2006-04-13 | — | — | WO | disclosed |
| US-20060014159-A1 | Methods of determining precise HERG interactions and designing compounds based on said interactions | NEURION PHARMACEUTICALS, INC. (US) | 2006-01-19 | — | — | US | disclosed |
| US-20060009511-A9 | N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor | CHEN ZHAOGEN | 2006-01-12 | — | — | US | disclosed |
| EP-1578992-A2 | METHODS OF DETERMINING PRECISE HERG INTERACTIONS AND ALETRING COMPOUNDS BASED ON SAID INTERACTIONS | Neurion Pharmaceuticals, Inc. (US) | 2005-09-28 | — | — | EP | disclosed |
| WO-2005086611-A2 | METHODS OF PRECISE MOLECULAR-LEVEL DETERMINATION OF LIGAND-RECEPTOR INTERACTIONS AND DESIGNING SELECTIVE DRUG COMPOUNDS BASED ON SAID INTERACTIONS | NEURION PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| US-20050009103-A1 | Methods of precise molecular-level determination of ligand-receptor interactions and designing selective drug compounds based on said interactions | NEURION PHARMACEUTICALS (US) | 2005-01-13 | — | — | US | disclosed |
| US-20040259256-A1 | Methods of unnatural amino acid incorporation in mammalian cells | NEURION PHARMACEUTICALS | 2004-12-23 | — | — | US | disclosed |
| WO-2004085463-A2 | METHODS OF UNNATURAL AMINO ACID INCORPORATION IN PROTEINS IN MAMMALIAN CELLS | NEURION PHARMACEUTICALS (US) | 2004-10-07 | — | — | WO | disclosed |
| US-20040180401-A1 | Methods of determining precise HERG interactions and designing compounds based on said interactions | NEURION PHARMACEUTICALS, INC. (US) | 2004-09-16 | — | — | US | disclosed |
| WO-2003100082-A2 | METHODS OF DETERMINING PRECISE HERG INTERACTIONS AND ALTERING COMPOUNDS BASED ON SAID INTERACTIONS | NEURION PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009511-A9 | N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor | HTR6, HTR2C, HTR1B | GPR84 125/4885TNF 4772/4885RIPK1 4494/4885 |
| US-20060014159-A1 | Methods of determining precise HERG interactions and designing compounds based on said interactions | KCNN4, KCNC1, HCN4 | GPR84 2994/4885TNF 4851/4885RIPK1 3766/4885 |
| US-20240150313-A1 | TRI-SUBSTITUTED INDOLE BINDING FUNCTION 3 (BF3) COMPOUNDS AND METHODS FOR THEIR USE | KLK3, BRDT, HTR3A | GPR84 1866/4885TNF 4829/4885RIPK1 2516/4885 |
| US-20040180401-A1 | Methods of determining precise HERG interactions and designing compounds based on said interactions | KCNN4, KCNC1, HCN4 | GPR84 2994/4885TNF 4851/4885RIPK1 3766/4885 |
| US-11453676-B2 | Inhibitors of protein arginine deiminases | PADI2, PADI1, PADI4 | GPR84 3228/4885TNF 3904/4885RIPK1 763/4885 |
| US-12018033-B2 | Inhibitors of protein arginine deiminases | PADI2, PADI1, PADI4 | GPR84 3335/4885TNF 4080/4885RIPK1 806/4885 |
| US-20050009103-A1 | Methods of precise molecular-level determination of ligand-receptor interactions and designing selective drug compounds based on said interactions | FSHR, SRPRB, SRPRA | GPR84 201/4885TNF 4151/4885RIPK1 1645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.